Press-release for stocks related to therapeutics for qlgn

Prices are updated after-hours

tags : Therapeutics symbols : Qlgn

save search

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
MRZM | $0.095 1031.22% 2.2K

Information

| 72.73% | O: 0.0% H: 72.73% C: 72.73%
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -1.84% | O: -4.91% H: 3.23% C: -3.29%
for commercialization therapeutics agreement

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -17.44% | O: 3.2% H: 0.0% C: -0.28%
qn-302 association positive cancer research meeting therapeutics

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Published: 2023-11-14 (Crawled : 22:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -56.46% | O: 4.76% H: 0.0% C: -4.55%
update therapeutics

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -54.29% | O: 2.86% H: 4.17% C: 0.38%
qn-302 tumors treatment trial therapeutics

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Published: 2023-09-27 (Crawled : 14:30) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -69.23% | O: 0.96% H: 0.0% C: -1.9%
qn-302 cancer pancreatic therapeutics

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -69.81% | O: -0.94% H: 0.0% C: -1.83%
qn-302 tumors treatment therapeutics

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -71.68% | O: 10.62% H: 0.8% C: -9.6%
qn-302 fda tumors treatment clearance trial therapeutics

Qualigen Therapeutics Divests FastPack® Diagnostics Business
Published: 2023-07-24 (Crawled : 12:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -69.23% | O: 0.48% H: 0.0% C: -0.48%
fastpack business diagnostics therapeutics

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
Published: 2023-04-18 (Crawled : 13:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -68.16% | O: 0.5% H: 3.16% C: -5.95%
qn-302 association cancer research meeting therapeutics

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
Published: 2023-04-18 (Crawled : 12:00) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -68.16% | O: 0.5% H: 3.16% C: -5.95%
qn-247 breast association cancer research meeting therapeutics negative

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-03-15 (Crawled : 13:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -68.93% | O: 4.85% H: 0.0% C: -6.48%
research meeting association therapeutics cancer

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
Published: 2023-03-09 (Crawled : 15:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -72.65% | O: -1.71% H: 2.61% C: -1.23%
conference association program therapeutics cancer

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
Published: 2023-02-01 (Crawled : 14:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -75.19% | O: 1.47% H: 13.07% C: 9.25%
therapeutics

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
Published: 2023-01-24 (Crawled : 14:20) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -75.0% | O: 3.13% H: 0.0% C: -3.03%
qn-302 therapeutics

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
Published: 2023-01-23 (Crawled : 14:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -74.6% | O: 3.97% H: 0.0% C: -2.29%
communications diagnostics therapeutics

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
Published: 2023-01-10 (Crawled : 16:00) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -74.8% | O: 20.47% H: 3.92% C: -12.42%
qn-302 designation drug therapeutics food cancer pancreatic

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
Published: 2023-01-05 (Crawled : 20:00) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K

Health Technology

| -76.74% | O: -0.44% H: 10.21% C: 10.21%
disease diagnostic therapeutics update platform

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Published: 2022-12-12 (Crawled : 14:00) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K

Health Technology